- Purpose of this Guideline
- Available ART Regimens
- General Principles in Choosing an Initial ART Regimen
- General Considerations with Initial ART Regimens
- Specific Factors to Consider and Discuss with Patients
- Special Considerations for Comorbid Conditions
- ART-Initiation Laboratory Testing
- ARV Dose Adjustments for Hepatic and Renal Impairment
- All Recommendations
- Updates to this Guideline
- Purpose and Development of This Guideline
- Rationale for and Efficacy of Injectable ART
- Benefits, Limitations, and Risks of CAB/RPV LA as ART
- Considerations for Implementation of CAB/RPV LA as ART
- Initiation and Maintenance of CAB/RPV LA as ART
- Laboratory Testing and Patient Follow-up
- All Recommendations
- How This Guideline Was Developed
Despite the challenges posed by the COVID-19 pandemic, expeditious initiation of antiretroviral therapy (ART) in people newly diagnosed with HIV remains a high priority and can be accomplished with modest adjustments to the established protocol. This guidance aims to assist primary care providers and other clinicians in adjusting the protocol for implementing rapid ART initiation during the COVID-19 pandemic.
Go to the guidance | Download PDF